Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.

There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some patients, prompting efforts to develop more potent CD33-directed therapeutics.

phage kills enteroaggregative without human microbiome dysbiosis.

Bacteriophage therapy can be developed to target emerging diarrhoeal pathogens, but doing so in the absence of microbiome disruption, which occurs with antibiotic treatment, has not been established. Identify a therapeutic bacteriophage that kills diarrhoeagenic enteroaggregative (EAEC) while leaving the human microbiome intact. Phages from wastewater in Portland, OR, USA were screened for bacteriolytic activity by overlay assay.